Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-13 9:09 pm Sale | 2023-12-31 | 13G | SCYNEXIS, Inc. SCYX | CAXTON CORP | 0 0.000% | -2,210,672 (Position Closed) | Filing History |
| 2024-02-13 9:00 pm Sale | 2023-12-31 | 13G | Savara Inc. SVRA | CAXTON CORP | 353,441 0.300% | -6,543,110 (-94.88%) | Filing History |
| 2023-02-14 1:27 pm Purchase | 2022-12-31 | 13G | Rezolute, Inc. RZLT | CAXTON CORP | 1,860,518 4.990% | 527,045 (+39.52%) | Filing History |
| 2023-02-14 12:47 pm Sale | 2022-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 983,607 2.200% | -2,495,733 (-71.73%) | Filing History |
| 2023-02-14 12:30 pm Sale | 2022-12-31 | 13G | Addex Therapeutics Ltd ADXN | CAXTON CORP | 35,942 0.900% | -79,782 (-68.94%) | Filing History |
| 2023-02-14 12:15 pm Sale | 2022-12-31 | 13G | Xeris Biopharma Holdings, Inc. XERS | CAXTON CORP | 5,973,324 4.400% | -1,856,358 (-23.71%) | Filing History |
| 2022-02-14 4:13 pm Purchase | 2021-12-31 | 13G | Cardiff Oncology, Inc. CRDF | CAXTON CORP | 3,479,340 8.100% | 380,893 (+12.29%) | Filing History |
| 2022-02-14 4:10 pm Purchase | 2021-12-31 | 13G | SCYNEXIS, Inc. SCYX | CAXTON CORP | 2,210,672 9.000% | 736,302 (+49.94%) | Filing History |
| 2022-02-14 4:07 pm Sale | 2021-12-31 | 13G | Addex Therapeutics Ltd ADXN | CAXTON CORP | 115,724 6.000% | -90 (-0.08%) | Filing History |
| 2022-02-14 4:04 pm Purchase | 2021-12-31 | 13G | Rezolute, Inc. RZLT | CAXTON CORP | 1,333,473 8.600% | 769,230 (+136.33%) | Filing History |
| 2022-02-14 4:01 pm Sale | 2021-12-31 | 13G | CTI BioPharma Corp. CTIC | CAXTON CORP | 2,239,300 2.300% | -1,510,590 (-40.28%) | Filing History |
| 2022-02-14 3:57 pm Sale | 2021-12-31 | 13G | Sierra Oncology, Inc. SRRA | CAXTON CORP | 1,119,322 7.000% | -23,039 (-2.02%) | Filing History |
| 2022-02-14 3:52 pm Unchanged | 2021-12-31 | 13G | Savara Inc. SVRA | CAXTON CORP | 6,896,551 6.100% | 0 (Unchanged) | Filing History |
| 2022-01-05 12:50 pm Sale | 2021-10-05 | 13D | Strongbridge Biopharma plc SBBP | CAXTON CORP | 0 0.000% | -10,280,682 (Position Closed) | Filing History |
| 2022-01-05 12:38 pm Purchase | 2021-10-05 | 13G | Xeris Biopharma Holdings, Inc. XERS | CAXTON CORP | 7,829,682 5.700% | 7,829,682 (New Position) | Filing History |
| 2021-03-19 4:53 pm Purchase | 2021-03-11 | 13G | Savara Inc. SVRA | CAXTON CORP | 6,896,551 6.200% | 6,896,551 (New Position) | Filing History |
| 2021-02-16 4:39 pm Purchase | 2020-12-31 | 13G | Sierra Oncology, Inc. SRRA | CAXTON CORP | 1,142,361 9.900% | 60,161 (+5.56%) | Filing History |
| 2021-02-16 4:23 pm Sale | 2020-12-31 | 13G | CTI BioPharma Corp. CTIC | CAXTON CORP | 3,749,890 5.100% | -737,427 (-16.43%) | Filing History |
| 2021-02-16 4:19 pm Purchase | 2020-12-31 | 13G | Addex Therapeutics Ltd ADXN | CAXTON CORP | 115,815 8.400% | 115,815 (New Position) | Filing History |
| 2021-02-16 4:06 pm Purchase | 2020-12-31 | 13G | SCYNEXIS, Inc. SCYX | CAXTON CORP | 1,474,370 7.500% | 1,474,370 (New Position) | Filing History |